Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

TDOC stock is oversold and undervalued as it beats Q3 earnings. The company has made significant acquisitions, which could pay off in 2022.

Teladoc Is Oversold and Undervalued With Positive Catalysts About to Kick in

Wall Street is looking for faster growth elsewhere.

Why Teladoc Health Stock Dove 32% in November

DocuSign

Roku

Investors are fleeing Cathe Wood's flagship fund. Here are three of the hardest-hit ARKK stocks and how to profit.

3 ARKK Stocks Being Ravaged by Bears That Are Top Picks Now

ARK Innovation ETF

Palantir Technologies

Spotify

Twitter

Zoom Video

All eyes are on the ARKK ETF as a majority of its growth holdings seem to be declining. Here are 5 losers that may warrant a second glance.

5 of Cathie Wood's Biggest Losers to Watch as the ARKK ETF Plunges Today

The virtual-care leader's shares are being pulled down with other growth stocks.

Why Teladoc Health Stock Is Tumbling This Week

AbbVie

Fulgent Genetics

Shares of these companies are gift-wrapped for those with patience.

3 Stocks That Could Make You Richer in December (and Beyond)

Moderna

After corrections, these big pandemic winners in 2020 are in stronger position for healthy gains next year as Covid stocks to buy. The post 3 Sickly Covid Stocks to Buy as Omicron Gets Around appeared first on InvestorPlace.

3 Sickly Covid Stocks to Buy as Omicron Gets Around

Apple

Canadian National Railway Company

Salesforce

Cirrus Logic

Ecolab

Etsy

Alphabet

Intuitive Surgical

NextEra Energy

NVIDIA

Old Dominion Freight Line

Pinterest

Stitch Fix

Shopify

Trex

Trade Desk

Take-Two Interactive Software

Waste Management

Zebra Technologies

How are the stocks doing? How are they doing versus the market and more important for Fools, why have the stocks done what they've done?

Monitoring Stock Picks

The market doesn't like TDOC stock at the moment, but a comeback could be in store as Teladoc rolls out a revolutionary primary-care service. The post Teladoc Is an Unappreciated Investment in Healthcare's Future appeared first on InvestorPlace.

Teladoc Is an Unappreciated Investment in Healthcare's Future

Shares are down 67% from highs earlier this year.

Teladoc Stock: Time to Buy?

Discovery

MercadoLibre

AT&T

The weather is turning colder, but these stocks could heat up your portfolio.

5 Top Stocks To Buy in December

Teladoc's slowing growth and increased spending indicates that its competition is increasingly tough, making TDOC stock a sell. The post Amid More Evidence of Tough Competition, Teladoc Stock Remains a Sell appeared first on InvestorPlace.

Amid More Evidence of Tough Competition, Teladoc Stock Remains a Sell

These three stay-at-home stocks are under pressure despite an initial pop.

Here's Why Pinterest, Teladoc, and Zoom Are Falling Tuesday

It was a hot investment during the early stages of the pandemic, but that isn't the case anymore.

Is Teladoc Health a Buy?

Chegg

Peloton

RingCentral

Stocks like Chegg, Peloton, RingCentral, Teladoc Health, and Zoom thrived during the pandemic. They might look like bargains now that they've taken a hit, but they're not. Workers are being called onsite. Kids are back in school. Work and communication tools like Chegg, Zoom, and RingCentral will continue to slow, despite Covid-19 variations.

These Stocks Soared During Pandemic, Then Sunk, But That Doesn't Make Them A Bargain Now

BARK

Lovesac Company

SSR Mining

These stocks have 10X return potential, or have already hit that mark and still look promising.

5 Stocks I Expect Will Make Me Wildly Rich by Retirement

Twilio

As Covid-19 cases rise again, could these tech stocks be worth investing in?

5 Stay-At-Home Stocks To Watch For The Future of Remote Work

These two innovative healthcare stocks have the opportunity to continue changing medicine.

Better Buy: Teladoc vs. Moderna

Longeveron

Merck

Novavax

Could rising coronavirus cases globally see these health care stocks be put back into the limelight?

4 Hot Health Care Stocks To Watch Right Now

Down nearly 50% this year, is the stock due for a rebound?

Why Teladoc Stock Popped on Wednesday

Another day, another analyst target price cut.

Why Teladoc Health Was Tumbling on Tuesday

Teladoc shareholders had a rough couple of months as shares declined by more than 40% YTD and are down roughly 60% from all-time highs in February. Telehealth has seen rapid uptake during the pandemic and utilization rates continue to be more than 30-times higher than pre-pandemic.

Teladoc: Understanding The Difference Between A Broken Company And A Broken Stock

Mr. Market is pummeling Teladoc in the wake of decelerating growth from Livongo and concerns about growing competition.

Teladoc Or Teladog? Why I'm Buying The Stock After Its Investor Day Dip

Lucid Group

The exponential growth potential for some stocks is simply too hard to ignore. And resist.

3 Solid Growth Stocks That Could Be Huge Winners in the Next Decade and Beyond

Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.

News for Teladoc Stock (TDOC)